Fatal splenic rupture after discontinuing treatment by ibrutinib and venetoclax in relapse/refractory mantle cell lymphoma

Author(s):  
Louise Roulin ◽  
Corinne Haioun ◽  
François Lemonnier
2016 ◽  
Vol 146 (suppl_1) ◽  
Author(s):  
Kriselle Lao ◽  
Ramona Untanu ◽  
Christopher Curtiss ◽  
Abirami Sivapiragasam ◽  
Neerja Vajpayee

2019 ◽  
Vol 2019 ◽  
pp. 1-4 ◽  
Author(s):  
Jared Williams ◽  
Shingi Chiruka

Mantle cell lymphoma is a relatively rare type of mature B-cell non-Hodgkin’s lymphoma with an incidence of approximately 8 cases per million persons per year. In patients with mantle cell lymphoma, there are rare case reports of the potentially life-threatening consequences of splenic rupture and rituximab-induced acute thrombocytopenia (RIAT) occurring separately, but there are no reports of these occurring in the same patient. Whilst rare, they are important to be aware of as early detection may prevent fatal outcomes.


2001 ◽  
Vol 41 (1-2) ◽  
pp. 197-201 ◽  
Author(s):  
A. H. Strickland ◽  
K. A. Marsden ◽  
J. McArdle ◽  
R. M. Lowenthal

2002 ◽  
Vol 3 (2) ◽  
pp. 117-120 ◽  
Author(s):  
Matthew A. Lunning ◽  
Maryalice Stetler-Stevenson ◽  
Peter T. Silberstein ◽  
Vincent Zenger ◽  
Gerald E. Marti

Sign in / Sign up

Export Citation Format

Share Document